# Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

> clinical trial · VERIFIED · 2026-07-02

Status: ACTIVE_NOT_RECRUITING · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Condition: Esophagogastric Adenocarcinoma

- Company: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05504720

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.